CRISPR–Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance
Pharmaceutics · 11.01.2026 · 18 (1) · 95
DOI: 10.3390/pharmaceutics18010095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.01.2026. Verfasst von Byeol Yoon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences, College of Pharmacy, Gyeongsang National University, Jinju 52828, Republic of Korea. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET), Regional Innovation System & Education (RISE) program.
Abstract (Originalsprache)
Antimicrobial resistance (AMR) is escalating worldwide, posing a serious threat to global public health by driving infections that are no longer treatable with conventional antibiotics. CRISPR–Cas technology offers a programmable and highly specific therapeutic alternative by directly targeting the genetic determinants responsible for resistance. Various CRISPR systems can restore antibiotic susceptibility and induce selective bactericidal effects by eliminating resistance genes, disrupting biofilm formation, and inhibiting virulence pathways. Moreover, CRISPR can suppress horizontal gene transfer (HGT) by removing mobile genetic elements such as plasmids, thereby limiting the ecological spread of AMR across humans, animals, and the environment. Advances in delivery platforms—including conjugative plasmids, phagemids, and nanoparticle-based carriers—are expanding the translational potential of CRISPR-based antimicrobial strategies. Concurrent progress in Cas protein engineering, spatiotemporal activity regulation, and AI-driven optimization is expected to overcome current technical barriers. Collectively, these developments position CRISPR-based antimicrobials as next-generation precision therapeutics capable of treating refractory bacterial infections while simultaneously suppressing the dissemination of antibiotic resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Institute of Pharmaceutical Sciences, College of Pharmacy, Gyeongsang National University, Jinju 52828, Republic of Korea.
- Hamlyn Centre for Robotic Surgery, Department of Mechanical Engineering, Imperial College London, London SW7 2AZ, UK.
ORCID-Profile: Jang Ah Kim, Yoo Kyung Kang
Förderung
- National Research Foundation of Korea (NRF)
- Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET)
- Regional Innovation System & Education (RISE) program
- CRUK Convergence Science Centre at The Institute of Cancer Research, London, and Imperial Col-lege London
- CRUK Convergence Science Centre at The Institute of Cancer Research, London, and Imperial College London
Zitieren
APA
Yoon, B., Kim, J. A., & Kang, Y. K. (2026). CRISPR–Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance. Pharmaceutics, 18(1), 95. https://doi.org/10.3390/pharmaceutics18010095
Vancouver
Yoon B, Kim JA, Kang YK. CRISPR–Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance. Pharmaceutics. 2026;18(1):95. doi:10.3390/pharmaceutics18010095
BibTeX
@article{Yoon2026,
author = {Yoon, Byeol and Kim, Jang Ah and Kang, Yoo Kyung},
title = {CRISPR–Cas-Mediated Reprogramming Strategies to Overcome Antimicrobial Resistance},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {1},
pages = {95},
doi = {10.3390/pharmaceutics18010095}
}
EUVIMED